PI Industries Limited — Q3 FY26 earnings call

Call held 13 Feb 2026

Management summary

P I Industries reported a mixed Q3 FY26, with strong 50% YoY growth in its Pharma business and robust margins, but AgChem exports moderated and domestic demand remained subdued due to industry headwinds. The company maintains a debt-free balance sheet with significant cash, is progressing on new molecule commercialization, and anticipates a gradual recovery from Q4 FY26, with growth momentum building into FY27.

Highlights

  • Pharma business delivered 50% year-on-year growth over nine months, driven by deepening relationships with innovators.

  • Gross Margin expanded to 59% during the quarter, supported by a favorable product mix and cost discipline.

  • EBITDA Margin for the 9-month period remained resilient at 27% despite industry headwinds.

  • Debt-free balance sheet with net cash of INR 35 billion provides strong resilience and flexibility for strategic investments.

  • The company is on track to commercialize 8 to 10 new molecules, with 5 already commercialized, and expects domestic growth to be back on track from FY27 onwards.

Concerns

  • Revenue for Q3 FY26 was INR 13,757 million, coming on a high base of previous years, indicating moderation.

  • Domestic agrochemical demand remained subdued due to high channel inventory, adverse weather conditions, and lower crop prices.

  • Trade working capital increased to 139 days of sales, reflecting current market conditions.

  • Pharma and Biologics businesses currently incur an INR 75-80 crore quarterly EBITDA loss, viewed as investment for future growth.

Key financials

2 periods

Headline

  • Revenue
    ₹1,375.7 Cr
  • Gross Margin
    59%
  • Net Cash
    ₹3,500 Cr
  • Contract Assets
    ₹1,065 Cr
  • Exceptional Income (Pharma)
    ₹126 Cr
  • Provisioning (Retirement Benefits)
    ₹20.9 Cr
  • Trade Working Capital Days
    139 days

9M

  • EBITDA Margin
    27%

What they filed

Q1 FY27: revenue down 9.6%, net profit down 26.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue2,131 1,780 1,648 1,769 1,753 −18%1,270 −29%1,391 −16%1,599 −10%
EBITDA685 545 504 574 607 −11%370 −32%385 −24%459 −20%
Net profit558 424 386 464 491 −12%282 −33%198 −49%342 −26%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex ₹500 Cr
    • Third multipurpose plant for specialty and electronic chemicals
    So broadly, it will be about INR 500 crore to INR 600 crore. And obviously, once we get through the whole process after Board approval, we will give you proper guidance next quarter.
  • Debt Net ₹3,500 Cr
    Our debt-free balance sheet position supported with net cash of INR 35 billion provides strong resilience and flexibility for strategic investments.
  • M&A PI Health Science Acquisition · Renegotiated · Consideration ₹[object Object] (undisclosed)

    Write-back of contingent consideration

    Exceptional income of INR 1,260 million from write-back of contingent consideration.

    During the quarter, net profit includes an exceptional income in our pharma business on account for a write-back of contingent consideration of INR 1,260 million which has been partly offset by additional provisioning of retirement benefits as per New Labour Code to the tune of INR 209 million.
  • Liquidity Cash ₹3,500 Cr Debt-free balance sheet with net cash provides strong resilience and flexibility for strategic investments.
    Our debt-free balance sheet position supported with net cash of INR 35 billion provides strong resilience and flexibility for strategic investments.

Guidance & targets

Revenue

  • Overall Revenue Growth Revenue · Q4 FY26 (recovery), FY27 (momentum) · Medium confidence Gradual recovery, momentum building
    While the operating environment remains cautious, we expect gradual recovery beginning quarter 4 FY26, with growth momentum building to FY27 as industry conditions stabilize and our new product stamp up.

    — Sanjay Agarwal

  • Domestic Business Growth Revenue · FY27 onwards · Medium confidence Back on track
    We expect the domestic growth to be back on track from FY27 onwards.

    — Sanjay Agarwal

  • CSM Business YoY Growth Revenue · FY27 · Medium confidence Turn positive
    We are pretty confident it will turn positive in FY27.

    — Mayank Singhal

Profitability

  • Gross Margin Profitability · Long-term · High confidence 50-52%
    maintain our long-term GP margin guidance between 50% to 52%, and we continue to move with that.

    — Mayank Singhal

  • Pharma EBITDA Profitability · Once topline hits INR 400-500 crore · Medium confidence Start moving positive
    But I do believe that now the foundations are set and it should start moving positive once we hit INR 400-500 crore of topline.

    — Mayank Singhal

Product Development

  • New Molecules Commercialized Product Development · On track · High confidence 8-10 new molecules (5 already commercialized)
    We are on track to commercialize 8 to 10 new molecules with 5 molecules already commercialized.

    — Mayank Singhal

  • Electronic Chemicals Molecules Commercialized Product Development · This year (FY26) · High confidence 4-5 molecules
    we expect that 4 to 5 molecules should be going for commercialization this year.

    — Atul Gupta

Regulatory

  • Pioxaniliprole Registration (India) Regulatory · Within next financial year (FY27) · High confidence Achieve registration
    The progress is that, within the next financial year, we should be achieving the registration. So that means a landmark in Indian history and the first Indian innovation in Ag-chem, Pioxaniliprole, will be commercialised in the coming financial year.

    — Mayank Singhal

Capex

  • FY27 Capex Plan Capex · FY27 · Medium confidence INR 500-600 crore
    So broadly, it will be about INR 500 crore to INR 600 crore. And obviously, once we get through the whole process after Board approval, we will give you proper guidance next quarter.

    — Mayank Singhal

What to watch in Q4 FY26

Pharma Intermediate Plant CAPEX Announcement

Next quarter
Current Plans to be announced
Target Specific CAPEX plans and timelines

Why it matters

Provides clarity on future investment in the pharma segment, crucial for growth.

Yes, we will be coming up with the plans and announcing that in the next quarter.

Risks & concerns

  • Global AgChem Industry Downturn

    high

    Prolonged down cycle driven by distributor destocking, adverse weather, soft commodity prices, and elevated interest rates.

    Management acknowledged

  • Domestic Agrochemical Demand Subdued

    medium

    Muted demand for key agrochemicals due to elevated channel inventories, adverse weather, and lower crop prices.

    Management acknowledged

  • Moderated Pharma/Biologics Momentum

    medium

    Near-term momentum moderated due to global biotech funding and ongoing geopolitical uncertainties, lengthening decision cycles.

    Management acknowledged

  • Elevated Trade Working Capital

    medium

    Trade working capital increased to 139 days of sales, reflecting current market conditions, but expected to improve.

    Management acknowledged

Q&A highlights

7 direct
FY27 Growth Outlook Direct
I think we see the positivity of growth... we will start seeing growth in FY27.

Clarifies management's expectation for a recovery year after current headwinds, though specific numbers are deferred.

Asked by Saurabh Jain

Gross Margin Sustainability Direct
maintain our long-term GP margin guidance between 50% to 52%, and we continue to move with that.

Addresses the sustainability of high gross margins seen this quarter, guiding to a slightly lower long-term range.

Asked by Saurabh Jain

Contract Assets Liquidation Partial
as we look at the past history, this is a typical cyclical approach and no inventory is kept beyond 3 to 6 months. So clearly, yes, at the end of the year, this will be coming down. And I think over the next couple of quarters we may further go lower.

Provides qualitative timeline for reduction of elevated contract assets, but no specific target number.

Asked by Abhijit Akella

Plant Healthcare (PHC) Business Progress Direct
on plant healthcare part of the business, we have made tremendous progress this year. We are expanding our business in Brazil, U.S., Mexico and European countries.

Details significant expansion and regulatory approvals in key international markets for the acquired PHC business.

Asked by Rohit Nagraj

Pharma & Biologics Investment and Profitability Direct
P&L charge for few more quarters. But thereafter, we think as an organization, these will be future growth engines for us.

Acknowledges current EBITDA losses in these segments but frames them as necessary investments for future growth, with a timeline for profitability linked to topline.

Asked by Siddharth Gadekar

FY27 Capex Plan Direct
So broadly, it will be about INR 500 crore to INR 600 crore. And obviously, once we get through the whole process after Board approval, we will give you proper guidance next quarter.

Provides an initial estimate for the next fiscal year's capital expenditure, indicating continued investment.

Asked by Tejas Pradhan

Working Capital Increase Direct
this is a reflection of the global scenario. We had one of the lowest working capital days across the industry. Now we have to accommodate the needs of our partners. And in those lines is where our net working capital days have gone up...

Explains the significant increase in working capital days as a response to global market conditions and partner needs, with an expectation for normalization.

Asked by Aditya Jhawar

Strategic Vision for Agri-Majors Landscape Direct
I think Pl is the only Company which is geared with this philosophy of partnership and technology. As an innovator, which creates an opportunity just not in manufacturing, but also in building new entities together. That is the Pl value proposition.

Provides insight into PI's long-term strategy of partnership and innovation to navigate the evolving global agricultural landscape.

Asked by Archit Joshi

3 min read 7 chapters

Detailed narrative

Global AgChem Headwinds and Stabilization Signals

The global crop protection market is in the latter phase of a prolonged down cycle, impacted by distributor destocking, adverse weather, soft commodity prices, and elevated interest rates. While product pricing remains soft, particularly for generics, channel inventories are gradually normalizing, and early signs of stabilization are emerging, with gradual improvement expected over the coming quarters. Farmer buying behavior is expected to remain cautious, sensitive to commodity realization and liquidity conditions.

Mixed Performance in AgChem Segments

AgChem exports moderated in Q3 FY26 due to demand softening and customer supply schedule adjustments, though new products in this segment showed 10% growth over nine months. Domestically, demand for agrochemicals remained subdued, primarily due to high channel inventories, lower commodity prices, and adverse weather, impacting high-value product sales. Management expects domestic growth to return to track from FY27 onwards, supported by new product launches and a strong product portfolio.

Pharma and Biologicals: Strategic Investments for Future Growth

The Pharma business demonstrated strong 50% year-on-year growth over nine months, driven by deepening relationships with biotech and big pharma innovators. While these segments currently incur a quarterly EBITDA loss of INR 75-80 crore, management views this as an investment for future growth, with profitability expected once the topline reaches INR 400-500 crore. The Biologicals segment is also progressing well, with regulatory approvals like Harpin αβ in India and ongoing international filings, aiming to build a scalable global franchise.

New Product Pipeline and Innovation

PI Industries is on track to commercialize 8-10 new molecules, with 5 already launched. A significant milestone is the impending registration of PIOXANILIPROLE, the first Indian-origin NCE in Ag-chem, expected within the next financial year. The company is also expanding its electronic chemicals portfolio, with 4-5 molecules anticipated for commercialization this year, targeting semiconductor and high-end electronics applications in global innovator markets, adding 5 new customers in this area.

Robust Financial Health and Capital Allocation

The company maintains a debt-free balance sheet with net cash of INR 35 billion, providing strong resilience and flexibility for strategic investments. Gross margins expanded to 59% in Q3, and the 9-month EBITDA margin stood at 27%, despite industry headwinds. For FY27, a broad CAPEX plan of INR 500-600 crore is anticipated, with specific plans for a pharma intermediate plant to be announced next quarter, alongside a third multipurpose plant for specialty and electronic chemicals.

Working Capital Management

Trade working capital days increased significantly to 139 days of sales, up from approximately 68 days YoY, reflecting current global market conditions and the need to accommodate partner requirements. Management acknowledges this increase but expects it to improve as market scenarios normalize in the coming quarters, noting that it is still better than industry benchmark norms.

Strategic Partnerships and ESG Focus

PIIND emphasizes its philosophy of partnership and technology as a key differentiator, enabling deeper collaboration from markets to research and building new entities. The company has also improved its S&P Global Corporate Sustainability ranking to the 98th percentile, featuring in the S&P Global Sustainability yearbook, highlighting its commitment to ESG principles and sustainable growth.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls